


Nezulcitinib

Cat. No.:	HY-132849
CAS No.:	2412496-23-0
Molecular Formula:	C ₃₀ H ₃₇ N ₇ O ₂
Molecular Weight:	527.66
Target:	JAK
Pathway:	Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation ^{[1][2]} .
IC ₅₀ & Target	JAK
In Vitro	Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor ^{[1][2]} . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Theravance's nezulcitinib fails to meet Phase II goals in Covid-19

[2]. Theravance biopharma, inc. Announces top-line results from phase 2 study of nezulcitinib in patients hospitalized with acute lung injury due to COVID-19

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA